Avella to Distribute Bayer’s Nexavar and Stivarga in US

Bayer has named Avella Specialty Pharmacy as one of the limited group of specialty pharmacies authorized to distribute two of its oral oncology drugs, Nexavar (sorafenib) and Stivarga (regorafenib) in the US market.

Nexavar is an oral medication used to treat certain cancers of the thyroid, kidney and liver. Nexavar was approved by the FDA to treat advanced kidney cancer in 2005. In 2007, the agency expanded the drug's label to treat liver cancer that cannot be surgically removed, and in late 2013, it was granted further approval to treat metastatic differentiated thyroid cancer.

Stivarga was approved by the FDA in 2012 for treatment of colorectal cancer.

Headquartered in Phoenix, Arizona, Avella Specialty Pharmacy is a National Accredited Specialty Pharmacy. The company said it is frequently selected by drug manufacturers to offer limited distribution drugs, due to its focus on clinical expertise, patient education, high-touch service and provider support.

Avella offers a nationwide distribution service as well as retail locations.